Platelet Disorder
9
2
3
2
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 49/100
11.1%
1 terminated out of 9 trials
66.7%
-19.8% vs benchmark
11%
1 trials in Phase 3/4
50%
1 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (9)
ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
Italian Study for Congenital Platelet Disorders
Rifaximin in Cirrhosis: Effects on Endotoxin and Haemostatic Indexes
Towards Improved Diagnostics for Suspected Platelet Function Disorders
PLATELET Function Assay With Flow Imaging on ImageSTREAM Cytometer
Avatrombopag to Promote Platelet Engraftment After Allo-HSCT
Avatrombopag for the Treatment of Thrombocytopenia After Donor Hematopoietic Stem Cell Transplant
Safety and Efficacy of Eltrombopag at Escalated Doses
Preoperative Dual Antiplatelet Therapy: Platelet Function and Influence of Cardiopulmonary Bypass